Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if his Department will take steps as part of the ongoing negotiations for the next Pharmaceutical Price Regulation Scheme to ensure that increasing the number of combination treatments for cancer can be considered cost-effective and made available for patients.

The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective innovative cancer treatments and technologies at a price the National Health Service can afford. Discussions on a branded medicines voluntary agreement for 2019 onwards are ongoing and are constructive.